October 31, 2022
October saw the SES team celebrate the launch of the Lupus Hub, supported by AstraZeneca and GSK.
The Lupus Hub, alongside the Psoriasis and Psoriatic Arthritis Hub, form SES’ independent medical education platforms within immunology. The Lupus Hub officially launched with the coverage of the 13th European Lupus Meeting in Stockholm, Sweden, on October 5, 2022, where our medical writing team on the ground delivered fantastic coverage.
After a successful launch period, we are delighted to highlight an overview of the engagement achieved within the immunology community:
If you are interested in supporting us to further the reach of the valuable education that the Lupus Hub provides to the immunology community, please get in touch with our Partnerships team.
The MDS International Guidelines is a project developed with the mission of raising the global standards of disease management in MDS through the development of contemporary and practical MDS treatment guidelines.
Hosted on a web-based, multi-channel platform with open access to users, the guidelines will be available in a responsive format suitable for phones, tablets, and computers. We hope to utilize mobile responsiveness to encourage daily use within clinical practice. We are seeking industry support to ensure that this project delivers its full potential and generates a comprehensive set of clinically advocated guidelines for use in the frontline hematology setting. Please contact email@example.com for further information.
We are delighted to welcome AstraZeneca as a supporter of the new Lupus Hub. The Lupus Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Joining GSK as a Platinum supporter, we look forward to seeing the collaboration with AstraZeneca grow along with the footprint of this exciting platform.
The AML Hub welcomes a new Bronze supporter—Kronos Bio. Kronos Bio’s support is a valued addition to the strong supporter network of AML stakeholders currently supporting the platform. The growing importance of measurable residual disease (MRD), both in diagnosis and treatment monitoring, reflects the support needed from organizations such as Kronos Bio, who are innovators in utilizing MRD as an endpoint within their clinical trial.
Bristol Myers Squibb will be continuing their support of the MPN Hub as a Gold level supporter in a resounding show of support to our commitment to medical education in MPN. As a critical industry stakeholder in MPN, we are pleased to develop the collaboration between the platform and the team at Bristol Myers Squibb.
We are seeking grants from our existing and new industry partners to support the delivery of new and innovative educational learning interventions for the hematology community. Through the delivery of these bespoke initiatives across our established learning platforms, we hope to demonstrate advanced levels of learning in targeted areas of unmet needs relevant to healthcare professionals.
CAR T-cell therapy – Cross-platform webinar series (Lymphoma, Multiple Myeloma, and ALL Hubs)
In a first for the hematology hubs, this series of webinars will address unmet educational needs pertaining to the growing scope of CAR T-cell therapies across the hematology indications. With consideration of the complex treatment journey from the initial consultation through to transition of care, this project aims to support healthcare professionals involved in this new and evolving treatment area, enabling them to make optimal treatment choices for their patients. Leveraging the remarkable reach of three relevant hub platforms, the content will also remain on the platforms as a valuable source of enduring content.
Please contact the Partnerships team on firstname.lastname@example.org if you would like to learn more about supporting these educational initiatives.
Looking to receive the latest news, project updates, and new offerings?